Characteristics | Oblique | Traditional | p |
---|---|---|---|
Operative time (min), median (IQR) | 149 (143–245) | 148 (108–261) | 0.86 |
IVC clamping time (min), median (IQR) | 18 (12–20) | 20 (14–23) | 0.41 |
Estimated blood loss (ml), median (IQR) | 300 (100–800) | 500 (175–738) | 0.51 |
Patients receiving transfusion, n (%) | 4 (36.4) | 5 (50) | 0.67 |
Transfer to intensive care unit, n (%) | 3 (27.3) | 3 (30) | 1.00 |
Days to surgical drain removal, median (IQR) | 4 (3–5) | 5 (4–7) | 0.05 |
Days to full ambulation, median (IQR) | 3 (3–3) | 2 (2–3) | 0.17 |
Days to oral feeding, median (IQR) | 2 (2–3) | 3 (2–6) | 0.28 |
Postoperative hospital stay (days), median (IQR) | 7 (5–10) | 8 (5–9) | 0.86 |
ASA grade, n (%) | 0.21 | ||
Grade II | 8 (72.7) | 10 (100) | |
Grade III | 3 (27.3) | 0 | |
Postoperative complication, n (%) | 0.06 | ||
Grade I | 4 (36.4) | 0 | |
Grade II | 2 (18.2) | 6 (60) | |
Grade III | 0 | 0 | |
Grade IV | 0 | 0 | |
Preoperative Hb (g/l), mean (SD) | 135 (13.2) | 117 (23.3) | 0.05 |
Postoperative Hb (g/l), mean (SD) | 110 (18.0) | 104 (19.8) | 0.50 |
Preoperative serum Cr (μmol/l), mean (SD) | 73 (20.1) | 96 (28.7) | 0.06 |
Postoperative (1 week) serum Cr (μmol/l), mean (SD) | 98 (37.7) | 120 (30.0) | 0.19 |
Serum Cr at follow-up (3 months; μmol/l), mean (SD) | 95 (21.1) | 131 (30.7) | 0.03* |
Preoperative serum BUN (mmol/l), mean (SD) | 5.3 (1.2) | 5.8 (2.3) | 0.53 |
Postoperative (1 week) serum BUN (mmol/l), mean (SD) | 4.6 (2.1) | 6.3 (3.4) | 0.19 |
Serum BUN at follow-up (3 months; mmol/l), mean (SD) | 5.7 (1.3) | 7.2 (2.5) | 0.18 |
Postoperative histology, n (%) | 0.33 | ||
ccRCC | 9 (81.8) | 5 (50) | |
Papillary RCC | 0 | 2 (20) | |
Unclassified RCC | 1 (9.1) | 0 | |
Xp11.2 RCC | 0 | 1 (10) | |
Urothelial carcinoma | 0 | 1 (10) | |
Angiomyolipoma | 1 (9.1) | 1 (10) | |
Tumor grade, n (%) | 0.07 | ||
Grade II | 5 (55.6) | 1 (10) | |
Grade III | 1 (11.1) | 5 (50) | |
Grade IV | 3 (33.3) | 2 (20) | |
Perirenal fat invasion, n (%) | 2 (18.2) | 1 (10) | 1.00 |
IVC wall invasion, n (%) | 0 | 5 (50) | 0.01* |
Presence of bland thrombus, n (%) | 0 | 3 (30) | 0.09 |
Presence of renal vein branch tumor thrombus, n (%) | 0 | 1 (10) | 0.48 |
Lymph node metastasis, n (%) | 4 (36.4) | 2 (20) | 0.36 |
Distant metastasis, n (%) | 6 (54.5) | 1 (10) | 0.06 |
Preoperative targeted therapy, n (%) | 1 (9.1) | 0 | 1.00 |
Adjuvant targeted therapy, n (%) | 8 (72.7) | 3 (30) | 0.09 |